| 臺大學術典藏 |
2022-04-21T06:50:18Z |
Impact of varying anatomic sites on advanced stage and survival of oral cancer: 9-year prospective cohort of 27 717 cases
|
Su W.W.-Y.; Su C.-W.; Chang D.-C.; Chuang S.-L.; Chen S.L.-S.; Hsu C.-Y.; Yen A.M.-F.; Chiu S.Y.-H.; Fann J.C.-Y.; Lee Y.-H.; Jeng Y.-C.; Lee Y.-C.; Chiu H.-M.; Chen, Tony Hsiu Hsi; Wang C.-P.; Chen M.-K. |
| 臺大學術典藏 |
2022-04-21T06:50:18Z |
Risk for a second primary hypopharyngeal and esophageal cancer after an initial primary oral cancer
|
Su W.W.-Y.; Chuang S.-L.; Yen A.M.-F.; Chen S.L.-S.; Fann J.C.-Y.; Chiu S.Y.-H.; Chiu H.-M.; Su C.-W.; Hsu C.-Y.; Chen M.-K.; Chen, Tony Hsiu Hsi; Wang C.-P.; Lee Y.-C. |
| 臺大學術典藏 |
2022-04-21T06:50:04Z |
Mitigating the impact of COVID-19 on colorectal cancer screening: Organized service screening perspectives from the Asia-Pacific region
|
Chiu H.-M.; Su C.-W.; Hsu W.-F.; Jen G.H.-H.; Hsu C.-Y.; Chen S.L.-S.; Chen, Tony Hsiu Hsi |
| 臺大學術典藏 |
2022-02-23T02:12:31Z |
Aboriginal Taiwanese hepatitis B carriers have more favorable viral factors than Han Chinese carriers
|
Nien H.-C.; Sheu J.-C.; Kao J.-H.; Chou H.-C.; Su C.-W.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-23T02:12:24Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-22T05:34:23Z |
Aboriginal Taiwanese hepatitis B carriers have more favorable viral factors than Han Chinese carriers
|
Nien H.-C.; Sheu J.-C.; Kao J.-H.; Chou H.-C.; Su C.-W.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:15Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-18T06:28:49Z |
Mitigating the impact of COVID-19 on colorectal cancer screening: Organized service screening perspectives from the Asia-Pacific region
|
Chiu H.-M.; Su C.-W.; WEN-FENG HSU; Jen G.H.-H.; Hsu C.-Y.; Chen S.L.-S.; Chen H.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:57Z |
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy
|
Tseng T.-C.; Yu M.-L.; CHUN-JEN LIU; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; Liu C.-H.; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:33Z |
Rapid prediction of treatment futility of boceprevir with peginterferon-ribavirin for Taiwanese treatment experienced hepatitis C virus genotype 1-infected patients
|
Yang C.-C.; Tsai W.-L.; Su W.-W.; Huang C.-F.; Cheng P.-N.; Lo C.-C.; Tseng K.-C.; Mo L.-R.; Wang C.-H.; Hsu S.-J.; Lai H.-C.; Su C.-W.; CHUN-JEN LIU; Peng C.-Y.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:16Z |
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions
|
Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; CHUN-JEN LIU; Kao J.-H.; Chuang W.-L.; Chen P.-J.; Chen D.-S. |
| 國立成功大學 |
2022 |
Optimization process parameters and adaptive quality monitoring injection molding process for materials with different viscosity
|
Su, C.-W.;Su, W.-J.;Cheng, F.-J.;Liou, G.-Y.;Hwang, S.-J.;Peng, H.-S.;Chu, H.-Y. |
| 國立成功大學 |
2022 |
Lepton flavor violation and scotogenic Majorana neutrino mass in a Stueckelberg U(1)X model
|
Chen, Chen C.-H.;Chiang, Chiang C.-W.;Nomura, T.;Su, C.-W. |
| 臺大學術典藏 |
2021-09-04T06:12:11Z |
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy
|
Tseng T.-C.; Yu M.-L.; Liu C.-J.; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; Liu C.-H.; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:06Z |
Aboriginal Taiwanese hepatitis B carriers have more favorable viral factors than Han Chinese carriers
|
Nien H.-C.; Sheu J.-C.; JIA-HORNG KAO; Chou H.-C.; Su C.-W.; Chen C.-H. |
| 臺大學術典藏 |
2021-09-04T05:16:55Z |
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions
|
Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; Liu C.-J.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-09-02T00:03:47Z |
Establishment of an immunocompetent metastasis rat model with hepatocyte cancer stem cells
|
Wu S;Tseng I.-C;Huang W.-C;Su C.-W;Lai Y.-H;Lin C;Lee A.Y.-L;Kuo C.-Y;Su L.-Y;Lee M.-C;Hsu T.-C;Yu C.-H.; Wu S; CHE LIN et al. |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2021-08-05T02:36:56Z |
Automatic generation of 3D models from UAV-captured image data for immersive VR applications
|
Perng N.-H;Bai B.-S;Chen P.-H;Han J.-Y;Jiang M.-Y;Huang J.-H;Su C.-W;Chen P.-Y.; Perng N.-H; Bai B.-S; Chen P.-H; Han J.-Y; Jiang M.-Y; Huang J.-H; Su C.-W; Chen P.-Y.; PO-HAN CHEN |
| 臺大學術典藏 |
2021-08-05T02:36:43Z |
Automatic generation of 3D models from UAV-captured image data for immersive VR applications
|
Perng N.-H;Bai B.-S;Chen P.-H;Han J.-Y;Jiang M.-Y;Huang J.-H;Su C.-W;Chen P.-Y.; Perng N.-H; Bai B.-S; Chen P.-H; Han J.-Y; Jiang M.-Y; Huang J.-H; Su C.-W; Chen P.-Y.; JEN-YU HAN |
| 臺大學術典藏 |
2021-07-03T03:34:38Z |
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy
|
Tseng T.-C.; Yu M.-L.; Liu C.-J.; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; Liu C.-H.; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:34Z |
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions
|
Yu M.-L.;Hung C.-H.;Huang Y.-H.;Peng C.-Y.;Lin C.-Y.;Cheng P.-N.;Chien R.-N.;Hsu S.-J.;Liu C.-H.;Huang C.-F.;Su C.-W.;Huang J.-F.;Liu C.-J.;Kao J.-H.;Chuang W.-L.;Pei-Jer Chen;Chen D.-S.; Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; Liu C.-J.; Kao J.-H.; Chuang W.-L.; PEI-JER CHEN; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:33:19Z |
Ropeginterferon alfa-2b every 2?weeks as a novel pegylated interferon for patients with chronic hepatitis B
|
Huang Y.-W.; Hsu C.-W.; Lu S.-N.; Yu M.-L.; Su C.-W.; Su W.-W.; Chien R.-N.; Hsu C.-S.; Hsu S.-J.; Lai H.-C.; Qin A.; Tseng K.-C.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-06-01T07:03:11Z |
Hepatitis C virus infection: A risk factor for Parkinson's disease
|
Wu W.Y.-Y.; Kang K.-H.; Chen S.L.-S.; Chiu S.Y.-H.; Yen A.M.-F.; Fann J.C.-Y.; Su C.-W.; Liu H.-C.; Lee C.-Z.; WEN-MEI FU; Chen H.-H.; Liou H.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:49Z |
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy
|
Tseng T.-C.; Yu M.-L.; Liu C.-J.; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; CHEN-HUA LIU; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
